Description
Cock Bombs is a combination tablet of 50mg Sildenafil and 20mg Tadalafil. The combination is not clinically approved in any country; in the recreational community it’s used because of the complementary pharmacokinetics of the two PDE-5 inhibitors.
Per study reports the tablet combines two action profiles: Sildenafil with fast onset (30 min) and 3-5 hour half-life, plus Tadalafil with slower onset (45-60 min) and 17.5-hour half-life. Practically this yields an action profile with rapid start (Sildenafil-driven) and long taper (Tadalafil-driven) over 24-36 hours.
Mechanistically the two PDE-5 inhibitors don’t amplify each other synergistically but additively - both block the same enzyme. Effects on cGMP concentration in corpus cavernosum muscle are the same as with single compound, only the temporal profile is mixed.
Safety profile: the combination adds the side effects of both compounds, so headache, facial flushing, and nasal congestion are more frequent than under a single compound. Clinical data on chronic application of the combination is absent.
The tablet is more effective fasting (Sildenafil portion sensitive to fatty meals); in practice the community doses 30-60 min before activity.
You can order Cock Bombs as oral tablets in one bottle with 50mg Sildenafil + 20mg Tadalafil per tablet.
This information is for research and educational purposes only. No medical recommendations.
Risks & Safety
Cock Bombs sits in the mid range of the risk scale. Because the tablet combines two PDE-5 inhibitors, the side effects of both compounds add up.
Documented in studies and the literature:
- Nitrate interaction: combination with nitrates or NO donors is contraindicated - both compounds act via the same pathway, and the combo does not make the effect safer.
- Added side effects: headache, facial flushing and nasal congestion are more frequent than under a single compound because the effects of both substances combine.
- Priapism risk: a prolonged painful erection is a documented rare risk of the PDE-5 inhibitor class.
- Missing clinical combo data: clinical data on chronic application of the combination is absent, and the combo tablet is not approved in any country.
Monitoring via bloodwork is recommended. This classification does not replace medical advice. Risk and responsibility for any actual use lie entirely with the buyer.
Studies
- Oral Sildenafil in the Treatment of Erectile Dysfunction - NEJM 1998, Goldstein et al: Sildenafil approval study of dose-dependent efficacy.
- Efficacy and Safety of Tadalafil for the Treatment of Erectile Dysfunction: Results of Integrated Analyses - Journal of Urology 2002, Brock et al: Integrated analysis of five RCTs on the efficacy of tadalafil.
- The Clinical Pharmacokinetics of Phosphodiesterase-5 Inhibitors for Erectile Dysfunction - Journal of Clinical Pharmacology 2005, Gupta et al: Comparative review of the pharmacokinetics of both PDE-5 inhibitors contained in the combo.
- Phosphodiesterase 5 Inhibitors for Erectile Dysfunction - Annals of Pharmacotherapy 2005, Setter et al: Direct class comparison of PDE-5 inhibitors.
